Dae Won Kim, MD

Cancer Focus:
Anal Cancer, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Liver (Hepatocellular) Cancer, Pancreatic Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer

Dr. Kim received his MD degree from the Inha University School of Medicine, Incheon, South Korea. He then completed an Internal Medicine Residency at St. Luke’s Roosevelt Hospital Center, New York City (NY) and a Melanoma Immunotherapy Fellowship at MD Anderson Cancer Center, Houston, Texas. He recently completed a Medical Oncology Fellowship at the Moffitt Cancer Center and the University of South Florida.

Dr. Kim will specialize in the treatment of gastrointestinal cancers, with a focus on immunotherapy.

Education & Training

Fellowship:

• MD Anderson Cancer Center - Melanoma Immunotherapy
• H. Lee Moffitt Cancer Center and Research Institute - Medical Oncology

Residency:

• St. Luke's Roosevelt Hospital Center - Internal Medicine

Medical School:

• Inha University School of Medicine, Korea - MD

Clinical Trial 21917
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Herceptin (Trastuzumab); Neratinib (); Oxaliplatin (); Pembrolizumab (Keytruda); Trastuzumab (); eloxatin (Oxaliplatin); rhuMAb HER2 (Trastuzumab)
Status: Open

Clinical Trial 22002
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Condition: Multiple
Intervention: RMC-6236 ()
Status: Open

Clinical Trial 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Davis EW, Park MA, Basinski TL, Arnoletti JP, Bloomston M, Carson TL, Biachi De Castria T, Chen DT, Cortizas EM, Crowder SL, Genilo-Delgado M, Douglas WG, Huguet KL, Jiang K, Hodul PJ, Karolak A, Kim DW, Koomen JM, Menon AA, Mo Q, Mok SR, Molina-Vega MA, Moreno-Urazan L, Ahmed S, Parker NH, Pimiento JM, Rasool G, Sparks LM, Stewart PA, Tassielli AF, Teer JK, Trevino JG, Velanovich V, Wang X, Whelan CJ, Judge SM, Judge AR, Fleming JB, Malafa MP, Jeong D, Permuth JB. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep.34(9):1609-1617. Pubmedid: 40553455.
• DeSomma A, Maletz S, Basinski TL, Morales R, de Castria TB, Bloomston M, Chen DT, Douglas WG, Huguet KL, Jeong D, Jiang K, Kim DW, Luthra A, Pimiento JM, Rajasekhara S, Velanovich V, Park MA, Shields GS, Slavich GM, Permuth JB. Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative. BMC Cancer. 2025 Oct.25(1):1530. Pubmedid: 41062956. Pmcid: PMC12506433.
• Lin YC, Turner K, Rajasekhara S, Kim DW, de Castria TB, Nguyen OT, Hume E, Sprow O, Santiago C, Milano J, Riccardi D, Nardella N, Al-Jumayli M, Permuth JB, Hoffe S, Hembree T, Hong YR, Islam JY, Tabriz AA, Hodul PJ. Early Supportive and Nutritional Care For Adults With Pancreatic Cancer: A Pilot Study. J Pain Symptom Manag. 2025 Nov.70(5):490-502. Pubmedid: 40816695.
• Yu J, Laborde JM, Park R, Shahzad M, Kim Y, Cheon J, Imanirad I, Kim RD, Biachi de Castria T, Nardella NL, Malafa M, Denbo JW, Fleming JB, Hoffe SE, Frakes JM, Sinnamon AJ, Pimiento JM, Hodul PJ, Kim DW. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507279. Pmcid: PMC12153592.
• Abuhelwa Z, Kim DW. LOAd703 and chemotherapy combination in pancreatic cancer: insights from the LOKON001 study. Transl Gastroenterol Hepatol. 2025 Mar.10:21. Pubmedid: 40337771. Pmcid: PMC12056096.
• Al Zarkali O, Hussaini M, Kim DW, Yu HM, Ott P, Ali S. A Rare Case of Simultaneous Brain and Leptomeningeal Metastases in a Patient With Pancreatic Cancer. Cureus. 2025 Mar.17(3):e79923. Pubmedid: 40171334. Pmcid: PMC11961017.
• Nardella N, Xia BT, Allenson K, Oraiqat A, Fan W, Mo Q, Permuth J, Kim DW, Hodul P. Influence of Coping, Esteem, and Resilience on Caregiver Distress in Pancreatic Cancer Patient-Caregiver Dyads. Healthcare (Basel). 2025 Jan.13(2). Pubmedid: 39857142. Pmcid: PMC11765500.
• Permuth J, Park M, Davis E, Alhassan S, Arnoletti J, Basinski T, McKee A, Bloomston M, Carson T, de Castria TB, Chen DT, Cortizas E, Crowder S, Delgado MG, Douglas W, Fleming J, Hodul P, Huguet K, Jiang K, Kim DW, Koomen J, Luthra A, Malafa M, Menon A, Morales R, Merchant N, Meredith K, Mo Q, Molina-Vega M, Moreno-Urazan L, Olumoyin K, Parker N, Pimiento J, Rasool G, Rejniak K, Sansil S, Sparks L, Stewart P, Tassielli A, Teer J, Tran DV, Trevino J, Velanovich V, Whelan C, Jeong D, Judge S, Judge A. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Res Sq. 2025 Feb. Pubmedid: 39989973. Pmcid: PMC11844656.
• Kim DW, Kim RD, Jimenez MM, Kim Y, Mehta R. A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas. Oncologist. 2025 Dec.30(12). Pubmedid: 41335458. Pmcid: PMC12681051.
• Miao R, Blue K, Sommerer K, Shah A, Bottiglieri S, Del Cueto A, Berry DK, Ho TT, Hicks JK, Kim DW. PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience. Cancers (Basel). 2024 Oct.16(20). Pubmedid: 39456541. Pmcid: PMC11505755.
• Li Y, Lauriola M, Kim D, Francesconi M, D'Uva G, Shibata D, Malafa MP, Yeatman TJ, Coppola D, Solmi R, Cheng JQ. Editorial Expression of Concern: Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer. Oncogene. 2024 Mar.43(11):837. Pubmedid: 38378921.
• Hoffe SE, Aguilera TA, Parikh PJ, Ghaly MM, Herman JM, Caster JM, Kim DW, Costello J, Malafa MP, Moser EC, Kennedy EP, Terry K, Kurman M. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. Future Oncol. 2024 Mar.20(8):437-446. Pubmedid: 38264869. Pmcid: PMC10988540.
• Kim DW, Beato F, Kim Y, Tassielli AF, Dai R, Denbo JW, Hodul PJ, Malafa MP, Fleming JB. Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Oncotarget. 2024 Jul.15:441. Pubmedid: 38953899. Pmcid: PMC11218789.
• Kim DW, Kim YC, Kovari BP, Martinez M, Miao R, Yu J, Mehta R, Strosberg J, Imanirad I, Kim RD. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel). 2024 Jan.16(3). Pubmedid: 38339307. Pmcid: PMC10854756.
• Barnett RM, Jang A, Lanka S, Fu P, Bucheit LA, Babiker H, Bryce A, Meyer HM, Choi Y, Moore C, Garje R, Gao X, Kim DW, Chang RY, Gulhati P, Ramaker R, Bansal R, Zhang T, Oliver Sartor A, Armstrong AJ, Bilen MA, Barata P. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. Commun Med (Lond). 2024 Dec.4(1):256. Pubmedid: 39623081. Pmcid: PMC11612475.
• Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ. Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2024 Apr.43(16):1231. Pubmedid: 38443683. Pmcid: PMC11036537.
• Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. Contemp Clin Trials Commun. 2024 Apr.38:101271. Pubmedid: 38440777. Pmcid: PMC10910065.
• Palm RF, Boyer E, Kim DW, Denbo J, Hodul PJ, Malafa M, Fleming JB, Shridhar R, Chuong MD, Mellon EA, Frakes JM, Hoffe SE. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy. HPB (Oxford). 2023 Sep.25(9):1110-1120. Pubmedid: 37286392.
• Kim DW, Beato F, Kim Y, Tassielli AF, Dai R, Denbo JW, Hodul PJ, Malafa MP, Fleming JB. Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Oncotarget. 2023 Sep.14:811-818. Pubmedid: 37713330. Pmcid: PMC10503742.
• Sarfraz H, Saha A, Jhaveri K, Kim DW. Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma. Curr Oncol. 2023 May.30(6):5322-5336. Pubmedid: 37366887. Pmcid: PMC10296812.
• Powers BD, Allenson K, Perone JA, Thompson Z, Boulware D, Denbo JW, Kim JK, Permuth JB, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Anaya DA. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Surg Open Sci. 2023 Mar.12:14-21. Pubmedid: 36879667. Pmcid: PMC9985051.
• Webking S, Sandoval ML, Chuong MD, Ucar A, Aparo S, De Zarraga F, Sahin I, Biachi T, Kim DW, Hoffe SE, Frakes JM, Palm RF. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Cancer Control. 2023 Jan.30. Pubmedid: 38038261. Pmcid: PMC10693219.
• Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, Kaiser A, Ucar A, Fleming J, De Zarraga F, Hodul P, Aparo S, Asbun H, Malafa M, Jimenez R, Denbo J, Frakes JM, Chuong MD. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). Cancer Control. 2023 Jan.30. Pubmedid: 36598464. Pmcid: PMC9982388.
• Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec.24(12):1387-1398. Pubmedid: 38039992.
• Powers BD, McDonald J, Mhaskar R, Lee SJC, Permuth JB, Vadaparampil S, Gilbert SM, Denbo JW, Kim DW, Pimiento JM, Hodul PJ, Malafa MP, Anaya DA, Fleming JB. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Ann Surg Open. 2022 Sep.3(3):e197. Pubmedid: 36199487. Pmcid: PMC9508964.
• Bryant JM, Palm RF, Liveringhouse C, Boyer E, Hodul P, Malafa M, Denbo J, Kim D, Carballido E, Fleming JB, Hoffe S, Frakes J. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Adv Radiat Oncol. 2022 Nov.7(6):101045. Pubmedid: 36420193. Pmcid: PMC9677195.
• Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, Kim RD. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. Eur J Cancer. 2022 Nov.176:171-180. Pubmedid: 36252287.
• Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul.169:93-102. Pubmedid: 35526308.
• Naffouje SA, Pointer DT, Satyadi MA, Hodul P, Anaya DA, Pimiento J, Malafa M, Kim DW, Fleming JB, Denbo JW. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Surg Endosc. 2022 Jul.36(7):4912-4922. Pubmedid: 34859301.
• Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 Feb.26(2):376-386. Pubmedid: 34506031.
• Xia BT, Otto AK, Allenson K, Kocab M, Fan W, Mo Q, Denbo JW, Malafa MP, Permuth JB, Kim DW, Fleming JB, Reblin M, Hodul PJ. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. J Behav Med. 2022 Dec.45(6):935-946. Pubmedid: 35986871.
• Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
• Bibok A, Kim DW, Malafa M, Kis B. Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer. World J Gastroenterol. 2021 Jul.27(27):4322-4341. Pubmedid: 34366607. Pmcid: PMC8316906.
• Fusco MJ, Saeed-Vafa D, Carballido EM, Boyle TA, Malafa M, Blue KL, Teer JK, Walko CM, McLeod HL, Hicks JK, Extermann M, Fleming JB, Knepper TC, Kim DW. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precis Oncol. 2021 Jan.5. Pubmedid: 34250383. Pmcid: PMC8232071.
• Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671939. Pmcid: PMC7919015.
• Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. J Surg Oncol. 2020 Nov.122(6):1074-1083. Pubmedid: 32673436.
• Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun.6(6):888-894. Pubmedid: 32352498. Pmcid: PMC7193528.
• Kim Y, Kim D, Cao B, Carvajal R, Kim M. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics. 2020 Jul.21(1):288. Pubmedid: 32631229. Pmcid: PMC7336455.
• Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist. 2020 Dec.25(12):e1893-e1899. Pubmedid: 32776632. Pmcid: PMC8186409.
• Kim DW, Schell MJ, Kim RD. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply. JAMA Oncol. 2020 Dec.6(12):1981-1982. Pubmedid: 33090188.
• Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB, Kim DW. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020 Aug.126(15):3464-3470. Pubmedid: 32453456. Pmcid: PMC7787270.
• Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2018 Oct.8(1):e1524695. Pubmedid: 30546965. Pmcid: PMC6287774.
• Kim R, Coppola D, Wang E, Chang YD, Kim Y, Anaya D, Kim DW. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget. 2018 May.9(34):23366-23372. Pubmedid: 29805739. Pmcid: PMC5955104.
• Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clin Lung Cancer. 2018 May.19(3):280-288.e4. Pubmedid: 29336998.
• Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 Jan.553(7688):347-350. Pubmedid: 29320474. Pmcid: PMC5773412.
• Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW, Hwu P, Hwu WJ, Patel SP, Liu M, Kim KB. Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiol. 2018 Dec.57:80-84. Pubmedid: 30347335.
• Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immun. 2017 Oct.66(10):1359-1366. Pubmedid: 28612140. Pmcid: PMC5898971.
• Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 Feb.5(2):100-105. Pubmedid: 28062513. Pmcid: PMC7055516.
• Kim DW, Zager JS, Eroglu Z. Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. Chin Clin Oncol. 2017 Feb.6(1):2. Pubmedid: 28285535.
• Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr.8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
• Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology-Basel. 2017 Apr.92(4):190-196. Pubmedid: 28152526.
• Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 Apr.123(8):1372-1381. Pubmedid: 27911979. Pmcid: PMC5384865.
• Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016 Sep.9(1):81. Pubmedid: 27595932. Pmcid: PMC5011857.
• Kim DW, Anderson J, Patel SP. Immunotherapy for uveal melanoma. Melanoma Manag. 2016 Jun.3(2):125-135. Pubmedid: 30190881. Pmcid: PMC6094800.
• Patel SP, Kim DW, Lacey CL, Hwu P. GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report. Medicine. 2016 Jan.95(4):e2336. Pubmedid: 26825879. Pmcid: PMC5291549.
• Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 Aug.122(15):2299-2312. Pubmedid: 26991400. Pmcid: PMC5567680.
• Kim DW, Barcena E, Mehta UN, Rohlfs ML, Kumar AJ, Penas-Prado M, Kim KB. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer. 2015 May.15:400. Pubmedid: 25962795. Pmcid: PMC4440312.
• McAleer MF, Kim DW, Trinh VA, Hwu WJ. Management of melanoma brain metastases. Melanoma Manag. 2015 Aug.2(3):225-239. Pubmedid: 30190852. Pmcid: PMC6094653.
• Kim DW, Patel SP. Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther. 2014 Sep.7:1631-1639. Pubmedid: 25278770. Pmcid: PMC4179759.
• Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. J Interferon Cytokine Res. 2014 Nov.34(11):915-919. Pubmedid: 24963699. Pmcid: PMC4217041.
• Kim DW, Trinh VA, Hwu WJ. Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov.14(11):1709-1718. Pubmedid: 25250971.
• Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med. 2014 May.12:113. Pubmedid: 24885155. Pmcid: PMC4062649.
• Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. Hum Gene Ther. 2014 May.25(5):452-460. Pubmedid: 24484178. Pmcid: PMC4027985.
• Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer. 2014 Jul.14:516. Pubmedid: 25030020. Pmcid: PMC4223398.
• Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer. 2014 Jan.2:1. Pubmedid: 24829758. Pmcid: PMC4019911.
• Shinozuka K, Dailey T, Tajiri N, Ishikawa H, Kim DW, Pabon M, Acosta S, Kaneko Y, Borlongan CV. Stem Cells for Neurovascular Repair in Stroke. J Stem Cell Res Ther. 2013 May.4(4):12912. Pubmedid: 24077523. Pmcid: PMC3783263.
• Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin. 2010 Oct.6(10):784-791. Pubmedid: 20975327. Pmcid: PMC9491320.
• Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010 Mar.17(3):718-730. Pubmedid: 19915919.
• Seo SW, Lee D, Minematsu H, Kim AD, Shin M, Cho SK, Kim DW, Yang J, Lee FY. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone. 2010 Mar.46(3):695-702. Pubmedid: 19895919. Pmcid: PMC2823832.
• Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 2009 Nov.69(21):8516-8525. Pubmedid: 19843856.
• Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 2009 May.8:28. Pubmedid: 19445670. Pmcid: PMC2689171.
• Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009 Jun.27(16):2645-2652. Pubmedid: 19364969. Pmcid: PMC2689845.
• Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009 Jan.7:2. Pubmedid: 19128501. Pmcid: PMC2631474.
• Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009 Feb.17(2):380-388. Pubmedid: 19034262. Pmcid: PMC2835064.
• Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol. 2008 Dec.181(11):8112-8119. Pubmedid: 19018004.
• Celil Aydemir AB, Lee S, Won Kim D, Gardner TR, Prince D, Mok Ahn J, Lee FY, Young-In Lee F. Nuclear factor of activated T cell mediates proinflammatory gene expression in response to mechanotransduction. Ann Ny Acad Sci. 2007 Nov.1117:138-142. Pubmedid: 17584983.
• Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007 Nov.5:60. Pubmedid: 18039393. Pmcid: PMC2217514.
• Minematsu H, Shin MJ, Celil Aydemir AB, Seo SW, Kim DW, Blaine TA, Macián F, Yang J, Lee FY, Young-In Lee F. Orthopedic implant particle-induced tumor necrosis factor-alpha production in macrophage-monocyte lineage cells is mediated by nuclear factor of activated T cells. Ann Ny Acad Sci. 2007 Nov.1117:143-150. Pubmedid: 18056040.
• Kim DW, Seo SW, Cho SK, Chang SS, Lee HW, Lee SE, Block JA, Hei TK, Lee FY. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res. 2007 Jun.25(6):820-828. Pubmedid: 17343283.
• Kim DW, Lee HJ, Karmin JA, Lee SE, Chang SS, Tolchin B, Lin S, Cho SK, Kwon A, Ahn JM, Lee FY. Mechanical loading differentially regulates membrane-bound and soluble RANKL availability in MC3T3-E1 cells. Ann Ny Acad Sci. 2006 Apr.1068:568-572. Pubmedid: 16831954.
• Lee FY, Kim DW, Karmin JA, Hong D, Chang SS, Fujisawa M, Takayanagi H, Bigliani LU, Blaine TA, Lee HJ. mu-Calpain regulates receptor activator of NF-kappaB ligand (RANKL)-supported osteoclastogenesis via NF-kappaB activation in RAW 264.7 cells. J Biol Chem. 2005 Aug.280(33):29929-29936. Pubmedid: 15955824.